InSite Vision Report issue

For profit Phase 3
Founded: Alameda CA United States (1986)
Status: Acquired by Sun Pharmaceuticals (2015)

Organization Overview

First Clinical Trial
2007
NCT00578955
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Insite Vision | InSite Vision

Active Ingredients

Drugs in Phase 3 Trials (4)

azithromycin (zithromax) (3 trials)

bromfenac (xibrom) (5 trials)

dexamethasone (2 trials)

urea (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blepharitis (Phase 3)

Cataract (Phase 3)

Conjunctivitis (Phase 3)

Dry Eye Syndromes (Phase 2)

Eye Diseases (Phase 2)

Inflammation (Phase 3)

Keratoconjunctivitis Sicca (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 4